 |
Also known as: VPRIV
The following information is NOT intended to endorse drugs or recommend therapy. While these reviews might be helpful, they are not a substitute for the expertise, skill, knowledge and judgement of healthcare practitioners in patient care.
Learn more about Velaglucerase alfa.
No reviews have yet been submitted. Be the first to review this drug.
The U.S. Food and Drug Administration today approved Elelyso (taliglucerase alfa) for long-term enzyme replacement therapy to treat a form of Gaucher disease,...
Elelyso (taliglucerase alfa) has been approved by the U.S. Food and Drug Administration as a long-term enzyme replacement therapy for people with a rare...
Feb 8, 2012 - Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), announced today four-year follow-up data from patients enrolled in the phase 2...
Looking for answers? Ask a question or go join the velaglucerase alfa support group to connect with others who have similar interests.
Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines & natural products. This material is provided for educational purposes only and is not to be used for medical advice, diagnosis or treatment.
Data sources include Micromedex™ (updated Apr 16th, 2012), Cerner Multum™ (updated May 18th, 2012), Wolters Kluwer™ (updated Apr 29th, 2012) and others.
To view content sources and attributions, refer to our editorial policy.
Copyright © 2000-2012 Drugs.com. All rights reserved.
We comply with the HONcode standard for trustworthy health information.
Verify here
